MTOR and non-small cell lung carcinoma: Additionally, we identified the enhancing effect of CD36 on NSCLC, which is contributed by the regulation of lipid metabolism and the AKT-mTOR pathway, indicating CD36 may be a novel target for NSCLC treatment.